FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2320196950> ?p ?o ?g. }

• W2320196950 abstract "Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FLGlucosamine and chondroitin, typically taken to treat osteoarthritis and chronic joint pain, are among the most commonly used non-vitamin, non-mineral, specialty supplements in the United States. These supplements have been shown to exhibit anti-inflammatory and anti-cancer properties in vitro and in vivo. Inflammation is thought to play an important role in cancer etiology and progression at several anatomic sites, including the lung. Studies have reported inverse associations of non-steroidal anti-inflammatory drug (NSAID) use and lung cancer risk; however, none have examined long-term use of glucosamine and chondroitin with lung cancer risk.The VITamins And Lifestyle (VITAL) study is a large, prospective cohort study designed to investigate the association of vitamin, mineral, and specialty supplements with cancer risk. Previously in this cohort, we found that glucosamine and chondroitin were inversely associated with lung cancer risk. We now evaluate these specific associations in more detail (by amount of use, histological subtypes of cancer) with an additional year of follow-up. Participants included 76,904 adults, 50-76 years, with no history of lung cancer, who were living in the region of western Washington State included in the Surveillance, Epidemiology, and End Results (SEER) cancer registry, and who completed a baseline questionnaire in 2000-2002. After 6 years of follow-up, 807 lung cancer cases were accrued. We characterized glucosamine and chondroitin use in the 10 years before baseline as non-use; low: <4 days/week or <4 years; high: ≥3 days/week and ≥4 years. We used multivariable-adjusted Cox regression to estimate hazard ratios (HR) and 95% confidence intervals (CI) for the association of glucosamine and chondroitin with lung cancer risk.Compared to non-use, high use was associated with a linear 33% reduction in risk (HR 0.67, 95% CI: 0.56-1.07, P-trend=0.04). There was no clear trend with high chondroitin use (HR 0.96, 95% CI: 0.67-1.37, P-trend=0.21). When stratified by histologic type, high use of glucosamine (HR 0.49, 95% CI: 0.27-0.90, P-trend<0.01) or chondroitin (HR 0.69, 95% CI: 0.36-1.31, P-trend=0.03) was strongly and inversely associated with risk of adenocarcinoma but not small cell or other non-small cell lung cancers. Factors associated with inflammation, including smoking, chronic-obstructive pulmonary disease, osteoarthritis, and NSAID use, did not modify these associations.The strength of the associations we observed is similar to those reported from studies of NSAIDs and lung cancer risk. Unlike NSAIDs, glucosamine and chondroitin carry few known adverse effects. Although confirmatory studies are needed, glucosamine and chondroitin may be potential lung cancer chemopreventive agents.Supported by NCI grants R25-CA94880, R01-CA154512, and K05-CA154337Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1912. doi:10.1158/1538-7445.AM2011-1912" @default.
• W2320196950 created "2016-06-24" @default.
• W2320196950 creator A5000172773 @default.
• W2320196950 creator A5016734907 @default.
• W2320196950 creator A5019716896 @default.
• W2320196950 creator A5075165389 @default.
• W2320196950 date "2011-04-15" @default.
• W2320196950 modified "2023-09-30" @default.
• W2320196950 title "Abstract 1912: Long-term use of glucosamine and chondroitin and lung cancer risk in the vitamins and lifestyle (VITAL) cohort" @default.
• W2320196950 doi "https://doi.org/10.1158/1538-7445.am2011-1912" @default.
• W2320196950 hasPublicationYear "2011" @default.
• W2320196950 type Work @default.
• W2320196950 sameAs 2320196950 @default.
• W2320196950 citedByCount "0" @default.
• W2320196950 crossrefType "proceedings-article" @default.
• W2320196950 hasAuthorship W2320196950A5000172773 @default.
• W2320196950 hasAuthorship W2320196950A5016734907 @default.
• W2320196950 hasAuthorship W2320196950A5019716896 @default.
• W2320196950 hasAuthorship W2320196950A5075165389 @default.
• W2320196950 hasConcept C121608353 @default.
• W2320196950 hasConcept C124490489 @default.
• W2320196950 hasConcept C126322002 @default.
• W2320196950 hasConcept C143998085 @default.
• W2320196950 hasConcept C178790620 @default.
• W2320196950 hasConcept C185592680 @default.
• W2320196950 hasConcept C188816634 @default.
• W2320196950 hasConcept C201903717 @default.
• W2320196950 hasConcept C2776256026 @default.
• W2320196950 hasConcept C2778125326 @default.
• W2320196950 hasConcept C71924100 @default.
• W2320196950 hasConcept C72563966 @default.
• W2320196950 hasConceptScore W2320196950C121608353 @default.
• W2320196950 hasConceptScore W2320196950C124490489 @default.
• W2320196950 hasConceptScore W2320196950C126322002 @default.
• W2320196950 hasConceptScore W2320196950C143998085 @default.
• W2320196950 hasConceptScore W2320196950C178790620 @default.
• W2320196950 hasConceptScore W2320196950C185592680 @default.
• W2320196950 hasConceptScore W2320196950C188816634 @default.
• W2320196950 hasConceptScore W2320196950C201903717 @default.
• W2320196950 hasConceptScore W2320196950C2776256026 @default.
• W2320196950 hasConceptScore W2320196950C2778125326 @default.
• W2320196950 hasConceptScore W2320196950C71924100 @default.
• W2320196950 hasConceptScore W2320196950C72563966 @default.
• W2320196950 hasLocation W23201969501 @default.
• W2320196950 hasOpenAccess W2320196950 @default.
• W2320196950 hasPrimaryLocation W23201969501 @default.
• W2320196950 hasRelatedWork W1967331062 @default.
• W2320196950 hasRelatedWork W1994648461 @default.
• W2320196950 hasRelatedWork W1995907891 @default.
• W2320196950 hasRelatedWork W2008647035 @default.
• W2320196950 hasRelatedWork W2023259927 @default.
• W2320196950 hasRelatedWork W2041926204 @default.
• W2320196950 hasRelatedWork W2052386715 @default.
• W2320196950 hasRelatedWork W2091128539 @default.
• W2320196950 hasRelatedWork W2130829672 @default.
• W2320196950 hasRelatedWork W2145502209 @default.
• W2320196950 hasRelatedWork W2158402121 @default.
• W2320196950 hasRelatedWork W2243515025 @default.
• W2320196950 hasRelatedWork W2265675302 @default.
• W2320196950 hasRelatedWork W2303021872 @default.
• W2320196950 hasRelatedWork W2312949231 @default.
• W2320196950 hasRelatedWork W2334563019 @default.
• W2320196950 hasRelatedWork W2482263390 @default.
• W2320196950 hasRelatedWork W2565882906 @default.
• W2320196950 hasRelatedWork W3024546847 @default.
• W2320196950 hasRelatedWork W3186456677 @default.
• W2320196950 isParatext "false" @default.
• W2320196950 isRetracted "false" @default.
• W2320196950 magId "2320196950" @default.
• W2320196950 workType "article" @default.